{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:00:16Z","timestamp":1792144816183,"version":"4.4.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn\u2019s disease (CD), often results in significant morbidity among patients with moderate to severe forms. While biologics and small molecules are effective in inducing remission, many patients experience refractory disease or extraintestinal manifestations. This study assesses the safety and efficacy of dual-targeted therapy in IBD patients treated at the Inflammatory Bowel Disease Center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study examined 79 patients with UC or CD who received dual-targeted therapy at the University from October 2018 to August 2023. Data collected included demographics, disease characteristics, previous treatments, and clinical outcomes. Primary outcomes were endoscopic, radiographic, and patient-reported clinical improvements, with secondary outcomes focusing on safety profiles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 79 patients (42 UC, 37 CD), 97 dual-targeted therapy cases were analyzed, primarily involving a biologic combined with a JAK inhibitor (90.7%). The median therapy duration was 39.1 weeks. Endoscopic improvement occurred in 69% of matched samples, with significant differences between pre- and postdual-targeted therapy Mayo scores for UC (P\u2005=\u2005.002) and Simple Endoscopic Score for CD (SES-CD) scores for CD (P\u2005=\u2005.018). The median pre- and postdual-targeted therapy Mayo scores across matched samples were 3 (range 1-3) and 1 (range 0-3), respectively, and for SES-CD scores were 12 (range 0-36) and 4 (range 0-20), respectively. Clinical improvement was reported by 73.2% of patients, with notable reductions in ESR (median 19 [range 2-124] mm\/h to 9 [range 0-116] mm\/h, P\u2005=\u2005.006), CRP (median 8.0 [range 0.2-78.5] mg\/L to 3.0 [range 0.2-68.2] mg\/L, P\u2005&amp;lt;\u2005.001), and albumin levels (4.0 [range 2.2-4.9] mg\/dL to 4.2 [range 3.4-5.2], P\u2005&amp;lt;\u2005.001). Non-obesity was associated with both more endoscopic improvement (P\u2005=\u2005.002) and clinical improvement (P\u2005=\u2005.007). Adverse events occurred in 37 cases, predominantly upper respiratory tract infections and dermatologic issues, with no thromboembolic events reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dual-targeted therapy demonstrated efficacy in improving clinical and endoscopic outcomes in patients with severe, refractory IBD and exhibited an acceptable safety profile. Despite the promising results, further research is needed to confirm these findings and determine optimal therapy combinations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae057","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T18:59:48Z","timestamp":1729709988000},"source":"Crossref","is-referenced-by-count":10,"title":["Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease: A Retrospective Study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3379-7880","authenticated-orcid":false,"given":"Sonya","family":"Bhaskar","sequence":"first","affiliation":[{"name":"Division of Digestive Diseases and Nutrition, Morsani College of Medicine, University of South Florida , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Makovich","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases and Nutrition, Morsani College of Medicine, University of South Florida , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mhaskar","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases and Nutrition, Morsani College of Medicine, University of South Florida , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Coughlin","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases and Nutrition, Morsani College of Medicine, University of South Florida , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Seminerio-Diehl","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases and Nutrition, Morsani College of Medicine, University of South Florida , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"4","key":"2025012806474485900_CIT0001","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.3390\/ijms24043817","article-title":"Inflammatory bowel diseases and gut microbiota","volume":"24","author":"Haneishi","year":"2023","journal-title":"Int J Mol Sci."},{"issue":"3","key":"2025012806474485900_CIT0002","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025012806474485900_CIT0003","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"5","key":"2025012806474485900_CIT0004","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/ibd\/izy327","article-title":"A state-of-the-art review of new and emerging therapies for the treatment of IBD","volume":"25","author":"Chudy-Onwugaje","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025012806474485900_CIT0005","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2025012806474485900_CIT0006","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"issue":"13","key":"2025012806474485900_CIT0007","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/cells12131730","article-title":"Novel small molecules in IBD: current state and future perspectives","volume":"12","author":"Jefremow","year":"2023","journal-title":"Cells."},{"issue":"Apr","key":"2025012806474485900_CIT0008","doi-asserted-by":"publisher","first-page":"17562848231159452","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease","volume":"16","author":"Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"2025012806474485900_CIT0009","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2025012806474485900_CIT0010","doi-asserted-by":"publisher","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360."},{"issue":"8","key":"2025012806474485900_CIT0011","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MCG.0000000000001583","article-title":"Dual targeted therapy for the management of inflammatory bowel disease","volume":"55","author":"Haider","year":"2021","journal-title":"J Clin Gastroenterol."},{"issue":"5","key":"2025012806474485900_CIT0012","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"2025012806474485900_CIT0013","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12876-023-02938-6","article-title":"Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis","volume":"23","author":"Chu","year":"2023","journal-title":"BMC Gastroenterol."},{"issue":"6","key":"2025012806474485900_CIT0014","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","article-title":"Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig Dis Sci."},{"issue":"1","key":"2025012806474485900_CIT0015","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025012806474485900_CIT0016","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jcag\/gwad032","article-title":"Current evidence for combined targeted therapy for the treatment of inflammatory bowel disease","volume":"7","author":"Wetwittayakhlang","year":"2024","journal-title":"J. Can. Assoc. Gastroenterol.."},{"issue":"7","key":"2025012806474485900_CIT0017","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/s0016-5085(22)60514-6","article-title":"885: triple combination therapy with vedolizumab, adalimumab, and methotrexate in patients with high-risk Crohn\u2019s disease: interim analysis from the open-label, phase 4 Explorer trial","volume":"162","author":"Colombel","year":"2022","journal-title":"Gastroenterology."},{"issue":"4","key":"2025012806474485900_CIT0018","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025012806474485900_CIT0019","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/ecco-jcc\/jjaa149","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","volume":"15","author":"Privitera","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025012806474485900_CIT0020","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis","volume":"164","author":"Singh","year":"2023","journal-title":"Gastroenterology."},{"issue":"4","key":"2025012806474485900_CIT0021","doi-asserted-by":"publisher","first-page":"630","DOI":"10.14309\/ajg.0000000000000197","article-title":"Impact of obesity on disease activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in inflammatory bowel diseases","volume":"114","author":"Jain","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"2025012806474485900_CIT0022","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00384-022-04190-y","article-title":"Systematic review and meta-analysis: association between obesity\/overweight and surgical complications in IBD","volume":"37","author":"Jiang","year":"2022","journal-title":"Int J Colorectal Dis."},{"issue":"6","key":"2025012806474485900_CIT0023","doi-asserted-by":"publisher","first-page":"832","DOI":"10.14309\/ajg.0000000000000608","article-title":"Effect of lifestyle factors on outcomes in patients with inflammatory bowel diseases","volume":"115","author":"Rozich","year":"2020","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025012806474485900_CIT0024","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."},{"issue":"3","key":"2025012806474485900_CIT0025","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2025012806474485900_CIT0026","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s disease","volume":"69","author":"Miyatani","year":"2024","journal-title":"Dig Dis Sci."},{"issue":"6","key":"2025012806474485900_CIT0027","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2025012806474485900_CIT0028","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/ibd\/izab112","article-title":"Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases","volume":"27","author":"Alayo","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2025012806474485900_CIT0029","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis","volume":"19","author":"Deepak","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2025012806474485900_CIT0030","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae057\/60011217\/otae057.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/1\/otae057\/60011217\/otae057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/1\/otae057\/60011217\/otae057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:47:54Z","timestamp":1738046874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae057\/7833437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,30]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae057","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,23]]},"article-number":"otae057"}}